Nikkei reported on a press conference held yesterday in Tokyo by Pharmaceutical Research and Manufacturers of America Chairman Robert Bradway, during which he voiced apprehension about the GOJ policy of regulating prices for new drugs by saying: “It will have a serious impact on Japan’s future.” The businessman stressed that highly innovative pharmaceuticals are not valued properly under the Japanese system. While noting that the association asked the USTR in February to put Japan on its priority watch list in connection with intellectual property protection, the daily claimed that Bradway hinted at reaching out to the Trump administration to further open up the Japanese drug market to U.S. products.